Individuals, patients, patient organisations, health professionals, researchers, drug developers, public health authorities - join this year's campaign!
//
The European Association for the Study of the Liver and the United European Gastroenterology Federation fully support the Alliance for Biomedical Research in Europe’s call for a European Institute of Health.
At its General Assembly meeting held in Brussels at the [...]
Read more
EASL warns that the fight against non-communicable diseases (NCDs) needs to continue. The UN Political Declaration of the High-Level Meeting of the General Assembly on the Prevention and Control of Non-communicable diseases is just a starting point for this fight.
Read more
Following the press release of last week (displayed hereafter) the European Chronic Disease Alliance (ECDA) publishes a statement requesting European Heads of State attention - available as a pdf at the bottom of this page.
Geneva, 23rd August 2011 – The fight against [...]
Read more
The European Association for the Study of the Liver
FIRST VACCINE FOR VIRAL HEPATITIS C COULD BECOME A REALITY
Berlin, Germany, Saturday 02 April 2011: Early data from phase I trials of an HCV vaccine presented today at the International Liver Congress™ show encouraging results, with high immunogenicity and good safety [...]
Read more
The European Association for the Study of the Liver
TREATMENT WITH PegIFN-λ SHOWS SUPERIOR VIROLOGICAL RESPONSE AND IMPROVED SAFETY THAN PegIFNα-2a IN HCV PATIENTS
Could PegIFN-λ become the future standard of care in HCV treatment?
Berlin, Germany, 02 April 2011: Highly exciting new data presented today at the International [...]
Read more
The European Association for the Study of the Liver
QUADRUPLE THERAPY SHOWS 100% SUSTAINED VIROLOGICAL RESPONSE (SVR) FOR HCV PATIENTS PREVIOUSLY UNRESPONSIVE TO TREATMENT
Is this treatment approach the next HCV therapy frontier?
Berlin, Germany, Saturday 02 April 2011: Exciting new data presented today at the [...]
Read more
The European Association for the Study of the Liver
ENTRY INHIBITORS SHOW PROMISE AS DRUGS WITH NEW MOA FOR TREATMENT OF HBV AND HDV INFECTION
First new hepatitis B and D treatment for many years
Berlin, Germany, Saturday 02 April 2011: Promising new viral hepatitis data presented today at the International Liver Congress™ [...]
Read more
The European Association for the Study of the Liver
NEW DATA SUGGESTS LIVER EXPERTS SHOULD EXERCISE CAUTION WHEN PRESCRIBING NOVEL ANTIVIRAL HCV DRUGS
Rapid resistance to novel anti-viral therapy develops in response to direct antiviral drugs
Berlin, Germany, Thursday 31 March 2011: Data presented at the International Liver [...]
Read more
The European Association for the Study of the Liver
THALIDOMIDE SHOWS EFFICACY AS ADJUVANT THERAPY FOR HEPATOCELLULAR CARCINOMA PATIENTS
Well-known drug provides new hope for difficult to treat liver cancer patients
Berlin, Germany, Saturday 02 April 2011: Thalidomide has shown potential to be used as the first adjuvant therapy [...]
Read more
The European Association for the Study of the Liver
NEW 10 YEAR DATA SHOWS NON-ALCOHOLIC FATTY LIVER DISEASE WILL REACH EPIDEMIC STATUS IN THE U.S.
Berlin, Germany, 31 March 2011: According to new data presented today at the International Liver Congress™, the United States (U.S.) could soon be faced with an epidemic of [...]
Read more
